SAN DIEGO, June 12, 2007 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. announced today that results from several research studies on the impact of chronic primary and transient insomnia were presented this week at the Associated Professional Sleep Societies (APSS) Annual Meeting. APSS highlights show that insomnia is significantly under-diagnosed and puts a significant strain on the Healthcare System and Labor Force. New data presented at APSS demonstrates the significant impact insomnia has on daytime functioning including workplace productivity, health, mood and quality of life, regardless of the type of sleep difficulty experienced.
"This research demonstrates that the impact of sleep difficulties on sufferers and the healthcare system is significant. Mounting research confirms that insomnia is a condition to be taken seriously and suggests that treating insomnia properly from the outset could reduce its subsequent impact, cost and safety consequences," said Christopher O'Brien M.D., Senior Vice President of Clinical Development and Chief Medical Officer of Neurocrine Biosciences.
APSS Presentation Highlights: Study Demonstrates that Insomnia is Significantly Under-Diagnosed -- The purpose of this study was to examine the prevalence and clinical characteristics of subtypes of insomnia in the general population. -- According to a survey of 14,997 U.S. adults, 43.3% of respondents self-reported sleeping difficulties related to insomnia; compared to only 8.5% who met the more stringent Diagnostic and Statistic Manual of Mental Disorders IV (DSM-IV) criteria for primary insomnia by self-reported symptoms. -- Results found that DSM-IV insomnia appears to be under-diagnosed and under-treated. Additionally, there are a significant number of individuals with insomnia, w
Page: 1 2 3 4 5
Related medicine technology :
1. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
2. Lux Biosciences Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007
3. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
4. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone